• Mashup Score: 1

    Direct oral anticoagulants (DOACs)—dabigatran, rivaroxaban, apixaban and edoxaban—are changing the landscape of clinical practice for patients requiring short and long-term anticoagulation. We report a patient with no history of kidney disease developing acute interstitial nephritis (AIN) after starting a DOAC, apixaban. To date, this is the first biopsy proven case of apixaban-induced AIN.

    Tweet Tweets with this article
    • Anyone ever seen #AIN in the setting of apixaban? @bmj_latest case report: https://t.co/YsLha0QVI2 #Nephrology #AKI #AskRenal https://t.co/MzL0dykLvz